Geir Erland Tjonnfjord

Prof. Dr. Geir Erland Tjonnfjord

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
GHGeir Hetland
Geir Hetland
JTJon-Magnus Tangen
Jon-Magnus Tangen
FMFaiza Mahmood
Faiza Mahmood
MMMohammad Reza Mirlashari
Mohammad Reza Mirlashari
LNLise Sofie Nissen-Meyer
Lise Sofie Nissen-Meyer
EJEgil Johnson
Egil Johnson
Since the 1980s, medicinal effects have been documented in scientific studies with the related Basidiomycota mushrooms Agaricus blazei Murill (AbM), Hericium erinaceus (HE) and Grifola frondosa (GF) from Brazilian and Eastern traditional medicine. Special focus has been on their antitumor effects, but the mushrooms’ anti-inflammatory and antiallergic properties have also been investigated. The antitumor mechanisms were either direct tumor attack, e.g., apoptosis and metastatic suppression, or indirect defense, e.g., inhibited tumor neovascularization and T helper cell (Th) 1 immune response. The anti-inflammatory mechanisms were a reduction in proinflammatory cytokines, oxidative stress and changed gut microbiota, and the antiallergic mechanism was amelioration of a skewed Th1/Th2 balance. Since a predominant Th2 milieu is also found in cancer, which quite often is caused by a local chronic inflammation, the three conditions—tumor, inflammation and allergy—seem to be linked. Further mechanisms for HE were increased nerve and beneficial gut microbiota growth, and oxidative stress regulation. The medicinal mushrooms AbM, HE and GF appear to be safe, and can, in fact, increase longevity in animal models, possibly due to reduced tumorigenesis and oxidation. This article reviews preclinical and clinical findings with these mushrooms and the mechanisms behind them.

15 January 2015 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
SBSimone Bürgler
Simone Bürgler
AGAleix Gimeno
Aleix Gimeno
APAnna Parente-Ribes
Anna Parente-Ribes
DWDong Wang
Dong Wang
AOAudun Os
Audun Os
LMLudvig Munthe
Ludvig Munthe
Chronic lymphocytic leukemia (CLL) is a B cell malignancy associated with increased levels of inflammatory cytokines. Similarly, expression of CD38 on CLL cells correlates with CLL cell survival and proliferation, but the mechanisms that regulate CD38 expression and inflammatory cytokines remain unclear. We have recently demonstrated that patients have CLL-specific Th cells that support CLL proliferation. In this article, we show that CLL cells attract such Th cells, thereby establishing an Ag-dependent collaboration. Blocking experiments performed in vitro as wells as in vivo, using a xenograft model, revealed that secretion of IFN-γ was a major mechanism by which CLL-specific Th cells increased CD38 on CLL cells. The expression of the transcription factor T-bet in peripheral blood CLL cells significantly correlated with CD38 expression, and transient transfection of CLL cells with T-bet resulted in T-bethiCD38hi cells. Finally, chromatin immunoprecipitation experiments revealed that T-bet can bind to regulatory regions of the CD38 gene. These data suggest that CLL cells attract CLL-specific Th cells and initiate a positive feedback loop with upregulation of T-bet, CD38, and type 1 chemokines allowing further recruitment of Th cells and increased type 1 cytokine secretion. This insight provides a cellular and molecular mechanism that links the inflammatory signature observed in CLL pathogenesis with CD38 expression and aggressive disease and suggests that targeting the IFN-γ/IFN-γR/JAK/STAT/T-bet/CD38 pathway could play a role in the therapy of CLL.

13 March 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
AMAgnieszka Małecka
Agnieszka Małecka
JDJan Delabie
Jan Delabie
IØIngunn Østlie
Ingunn Østlie
ATAnne Tierens
Anne Tierens
URUlla Randen
Ulla Randen
GTGunhild Trøen
Gunhild Trøen
Primary cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia caused by a distinct type of B-cell lymphoproliferative disease of the bone marrow.1

1 January 2014 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
JHJohanna A. Kremer Hovinga
Johanna A. Kremer Hovinga
GTGeir Erland Tjonnfjord
Geir Erland Tjonnfjord
IRIngrid M. Ringen
Ingrid M. Ringen
Bernhard LämmleBernhard Lämmle
Bernhard Lämmle
AWAnders Waage
Anders Waage
AKAnne-Sophie von Krogh
Anne-Sophie von Krogh

13 April 2023 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
JHJohanne U. Hermansen
Johanne U. Hermansen
YYYanping Yin
Yanping Yin
AUAleksandra Urban
Aleksandra Urban
CMCamilla V. Myklebust
Camilla V. Myklebust
LKLinda Karlsen
Linda Karlsen
SSSigrid S. Skånland
Sigrid S. Skånland
The microenvironment of chronic lymphocytic leukemia (CLL) cells in lymph nodes, spleen, and bone marrow provides survival, proliferation, and drug resistance signals. Therapies need to be effective in these compartments, and pre-clinical models of CLL that are used to test drug sensitivity must mimic the tumor microenvironment to reflect clinical responses. Ex vivo models have been developed that capture individual or multiple aspects of the CLL microenvironment, but they are not necessarily compatible with high-throughput drug screens. Here, we report on a model that has reasonable associated costs, can be handled in a regularly equipped cell lab, and is compatible with ex vivo functional assays including drug sensitivity screens. The CLL cells are cultured with fibroblasts that express the ligands APRIL, BAFF and CD40L for 24 h. The transient co-culture was shown to support survival of primary CLL cells for at least 13 days, and mimic in vivo drug resistance signals. Ex vivo sensitivity and resistance to the Bcl-2 antagonist venetoclax correlated with in vivo responses. The assay was used to identify treatment vulnerabilities and guide precision medicine for a patient with relapsed CLL. Taken together, the presented CLL microenvironment model enables clinical implementation of functional precision medicine in CLL.

23 August 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YYYanping Yin
Yanping Yin
PAPaschalis Athanasiadis
Paschalis Athanasiadis
LKLinda Karlsen
Linda Karlsen
AUAleksandra Urban
Aleksandra Urban
HXHaifeng Xu
Haifeng Xu
SSSigrid S. Skånland
Sigrid S. Skånland
Purpose: PI3K inhibitors (PI3Ki) are approved for relapsed chronic lymphocytic leukemia (CLL). Although patients may show an initial response to these therapies, development of treatment intolerance or resistance remain clinical challenges. To overcome these, prediction of individual treatment responses based on actionable biomarkers is needed. Here, we characterized the activity and cellular effects of 10 PI3Ki and investigated whether functional analyses can identify treatment vulnerabilities in PI3Ki-refractory/intolerant CLL and stratify responders to PI3Ki. Experimental Design: Peripheral blood mononuclear cell samples (n = 51 in total) from treatment-naïve and PI3Ki-treated patients with CLL were studied. Cells were profiled against 10 PI3Ki and the Bcl-2 antagonist venetoclax. Cell signaling and immune phenotypes were analyzed by flow cytometry. Cell viability was monitored by detection of cleaved caspase-3 and the CellTiter-Glo assay. Results: pan-PI3Kis were most effective at inhibiting PI3K signaling and cell viability, and showed activity in CLL cells from both treatment-naïve and idelalisib-refractory/intolerant patients. CLL cells from idelalisib-refractory/intolerant patients showed overall reduced protein phosphorylation levels. The pan-PI3Ki copanlisib, but not the p110δ inhibitor idelalisib, inhibited PI3K signaling in CD4+ and CD8+ T cells in addition to CD19+ B cells, but did not significantly affect T-cell numbers. Combination treatment with a PI3Ki and venetoclax resulted in synergistic induction of apoptosis. Analysis of drug sensitivities to 73 drug combinations and profiling of 31 proteins stratified responders to idelalisib and umbralisib, respectively. Conclusions: Our findings suggest novel treatment vulnerabilities in idelalisib-refractory/intolerant CLL, and indicate that ex vivo functional profiling may stratify PI3Ki responders.